

How ICER's Missteps Leave Access in Doubt For Atopic Dermatitis Patients

The Institute for Clinical and Economic Review finds new treatments for atopic dermatitis to be cost effective – justifying health plan coverage for the medications. But methodological missteps invite questions about how secure patients' access to the treatments will be.



Misstep #1

Calculate Treatment's Value Based on Non-existent Price

Report determines cost effectiveness before one therapy is even priced and available



Misstep #2

Undervalue Health Benefit without Long-term Data

Report evaluates effectiveness though long-term impact data doesn't yet exist – then uses the lack of data to justify reducing the net health benefit from a "B+" to a "C+"



Misstep #3

Overlook Crucial Patient Factors

Report fails to incorporate quality-of-life benefits that matter to patients



Misstep #4

Leave Access Subject to Tentative & Incomplete Information

Report bases analysis on incomplete data, offering tentative findings that may not supply the consistent, long-term access patients need



Do ICER's findings promise patient access?



Or set patients up for challenges to come?